Phio Pharmaceuticals Corp., 2025-11-12
An SEC Form D private-offering notice from King Of Prussia, PA, a $25,931,342 filer-stated offering target in Biotech. Filed 2025-11-12. The source filing is one click away. For companies that filed this week, open the live feed.
What this filing says
Clinical-stage biopharmaceutical company developing INTASYL siRNA gene silencing therapeutics to enhance immune cells against cancer, including a PD-1 silencing candidate for skin cancers.
This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.
Other Form D filings from the same week
each with its own page and its own EDGAR source- NEUROPATHIX, INC., 2025-11-17, $50M, Doylestown, PA
- AecorBio Inc., 2025-11-12, $2.5M, Menlo Park, CA
- IsoBio, Inc., 2025-11-14, $3M, Gladwyne, PA
- Prometheus Therapeutics Inc., 2025-11-12, $6.5M, Miramar, FL
- Shelfmark, Inc., 2025-11-12, $1.3M, Pittsburgh, PA
- PIPr Therapeutics, Inc., 2025-11-12, $2.5M, Durham, NC
The Monday digest, free
A summary of who raised money last week: the ones worth a call first, then every company that filed, by state and sector. One email, Monday mornings. No spam, unsubscribe anytime.
By subscribing you agree to our Terms and Privacy Policy.